THE DUBERSTEIN GROUP INC. for PHRMA INC.
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
21st Century Cures - HR 6, 21st Century Cures Act. Offsets to pay for Highway Trust Fund reauthorization - HR 22, DRIVE Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KENNETH DUBERSTEIN | — |
| DANIEL P MEYER | — |
| DAVID J SCHIAPPA | — |
Copyright/Patent/Trademark CPT
Patent reform - HR 9, Innovation Act; S 1137, PATENT Act; HR 2045, Targeting Rogue and Opaque Letters Act of 2015; S 632, STRONG Patents Act of 2015; HR 1896, Demand Letter Transparency Act of 2015.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL P MEYER | — |
Pharmacy PHA
Drug pricing - S 2023, Prescription Drug Affordability Act of 2015.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN GRIFFIN | — |
Taxation/Internal Revenue Code TAX
Comprehensive corporate and international tax reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL P MEYER | — |
Budget/Appropriations BUD
Debt limit and continuing resolution and possible healthcare related pay-fors - HR 719, Continuing Appropriations Act, 2016; proposed legislation re these issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL P MEYER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.